Back to Search
JAMES DAHLE, MD
MD
Emergency Medicine Physician
NPI: 1811963242IndividualAccepts Medicare
Specialties, Licenses & Credentials
Emergency Medicine PhysicianPrimary
Emergency Medicine
Code: 207P00000X
34192(AZ)
CMS Specialties
PrimaryEMERGENCY MEDICINE
Education
UNIVERSITY OF UTAH SCHOOL OF MEDICINE
Class of 2003
Research & Publications (20)
ED treatment of brainstem anesthesia after retrobulbar block.
PMID 17157702·Am J Emerg Med·2007
5-case
Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab.
PMID 19593562·Eur J Nucl Med Mol Imaging·2010
7-preclinical
In vitro cytotoxicity of low-dose-rate radioimmunotherapy by the alpha-emitting radioimmunoconjugate Thorium-227-DOTA-rituximab.
PMID 19679402·Int J Radiat Oncol Biol Phys·2009
8-other
Overexpression of human OGG1 in mammalian cells decreases ultraviolet A induced mutagenesis.
PMID 18406515·Cancer Lett·2008
7-preclinical
Reirradiation of recurrent breast cancer with and without concurrent chemotherapy.
PMID 18801165·Radiat Oncol·2008
8-other
Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.
PMID 18722269·Int J Radiat Oncol Biol Phys·2008
7-preclinical
Evaluation of the binding of radiolabeled rituximab to CD20-positive lymphoma cells: an in vitro feasibility study concerning low-dose-rate radioimmunotherapy with the alpha-emitter 227Th.
PMID 17803441·Cancer Biother Radiopharm·2007
8-other
A one-step method for determining the maximum number of bound antibodies, and the affinity and association rate constants for antibody binding.
PMID 17667754·Nucl Med Commun·2007
8-other
Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability.
PMID 17651051·Cancer Biother Radiopharm·2007
8-other
Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate.
PMID 17536011·Blood·2007
7-preclinical
Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy.
PMID 16546683·Nucl Med Biol·2006
7-preclinical
Bystander effects in UV-induced genomic instability: antioxidants inhibit delayed mutagenesis induced by ultraviolet A and B radiation.
PMID 16091149·J Carcinog·2005
8-other
The pheomelanin precursor 5-S-cysteinyldopa protects melanocytes from membrane damage induced by ultraviolet A radiation.
PMID 15808398·Cancer Lett·2005
7-preclinical
Bystander effects may modulate ultraviolet A and B radiation-induced delayed mutagenesis.
PMID 15733036·Radiat Res·2005
7-preclinical
Melanin synthesis may sensitize melanocytes to oxidative DNA damage by ultraviolet A radiation and protect melanocytes from direct DNA damage by ultraviolet B radiation.
PMID 15357843·Pigment Cell Res·2004
7-preclinical
Automated counting of mammalian cell colonies by means of a flat bed scanner and image processing.
PMID 15290719·Cytometry A·2004
4-observational
Increased level of oxidative stress in genomically unstable cell clones.
PMID 15043843·J Photochem Photobiol B·2004
7-preclinical
Pigmented melanocytes are protected against ultraviolet-A-induced membrane damage.
PMID 12925216·J Invest Dermatol·2003
4-observational
Induction of delayed mutations and chromosomal instability in fibroblasts after UVA-, UVB-, and X-radiation.
PMID 12670891·Cancer Res·2003
7-preclinical
Bystander effects in cell death induced by photodynamic treatment UVA radiation and inhibitors of ATP synthesis.
PMID 11332033·Photochem Photobiol·2001
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2005 E EDISON ST
TUCSON, AZ 85719 - Phone
- (520) 320-9556
Quick Facts
- NPI
- 1811963242
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 23
- Publications
- 20
Are you this provider?
Claim Your Profile